Regular low-dose aspirin use is associated with a 14 percent overall reduction in the adjusted odds of synchronous distant metastatic colorectal cancer at diagnosis, according to a nationwide Swedish study published on Saturday in the British Journal of Cancer.
Colorectal cancer ranks as the third most common malignancy and the second leading cause of cancer-related mortality globally. Projections anticipate a 71 percent surge in total burden by 2045, and approximately 20 percent of patients present with distant metastatic disease at diagnosis, a stage IV presentation that severely compromises prognosis.
Researchers analyzed information concerning 81,269 colorectal cancer patients gathered across a span of fourteen years via the Colorectal Cancer Database Sweden to see if routine pharmaceutical use influences these statistics. The cohort was compiled by Mehrnoosh Shahrivar, Caroline E. Dietrich, Bengt Glimelius, and colleagues, examining records from the Swedish Colorectal Cancer Registry linked with nationwide health and demographic registers.
Anatomical Divergence in Right and Left Colon Tumors
The inverse association between aspirin and metastasis appeared most pronounced among individuals diagnosed with right-sided colon tumors. Current aspirin use was linked to a 21 percent reduction in metastatic odds for right-sided lesions, a risk reduction that also extended to past aspirin users independently of exposure duration.
In contrast, this protective association did not consistently extend to left-sided colon malignancies, highlighting substantial anatomical differences in how aspirin interacts with colorectal cancer progression throughout the bowel.

Prescription Registers and Exposure Methodology
Sweden restricts low-dose aspirin (75 mg or 160 mg) to medical prescription, preventing untracked over-the-counter acquisition. Researchers tracked pharmaceutical exposure through the Swedish Prescribed Drug Register, which has maintained complete national capture of automated community pharmacy dispensations since July 1, 2005.
Exposure was defined as receiving at least 365 dispensed tablets prior to cancer diagnosis. Based on a presumed rate of one pill daily, this criterion equates to a minimum of one full year of cumulative treatment. Patients meeting this definition were categorized as current users if they dispensed the tablets within two years of diagnosis, while past users met the pill threshold earlier in their medical history.
Conflicting Aspirin Trial Results over Decades
Initial connections between aspirin and cancer biology emerged in 1972 through mouse models showing decreased metastasis, which was followed in 1988 by human epidemiological data indicating a lowered colorectal cancer risk. However, randomized trials assessing aspirin in cardiovascular prevention have yielded conflicting results over subsequent decades.
The ASPREE trial in older adults reported an increased risk of incident metastatic cancer among aspirin users. Large-scale observational register studies, such as the current Swedish analysis, became necessary because combined evaluations of previous prevention trials instead revealed a 31 percent drop in metastatic adenocarcinoma.
Common Questions on Aspirin and Colorectal Cancer
Who was included in the Swedish colorectal cancer study?
The study evaluated 81,269 patients aged 18 and older diagnosed with primary stage I through IV colorectal cancer in Sweden between 2008 and 2021 with no other cancer diagnosis in the preceding five years.
How was low-dose aspirin exposure measured?
Exposure required the dispensation of a minimum of 365 low-dose aspirin pills via the Swedish Prescribed Drug Register, equating to at least 12 months of use before the cancer diagnosis.
Founded in 1947 by the British Empire Cancer Campaign, the British Journal of Cancer originally appeared under the Macmillan Press imprint before shifting to Springer Nature in the 1980s.
Cancer Research UK retained ownership and editorial control until 2021, when declining charitable income during the pandemic prompted the sale to Springer Nature. The journal now publishes twice-monthly across six broad headings, including epidemiology and clinical studies, and its 2025 impact factor of 7.8 places it 43rd in oncology.
Does aspirin reduce metastasis for all types of colorectal cancer equally?
No, the protective association is most pronounced in right-sided colon cancer, where current users showed a 21 percent reduction in metastatic odds, while left-sided colon malignancies did not show the same consistent reduction.
Worth a look